Clinical trial · Interventional
A Study of ARQ 171 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors
NCT00398840CI-TRIAL-00026289terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ARQ 171 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the safety, tolerability and maximum tolerated dose (MTD) of ARQ 171
Secondary outcomes (2)
- measure
- To determine the pharmacokinetic profile of ARQ 171
- measure
- To assess the preliminary anti-tumor activity of ARQ 171
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent must be obtained and documented prior to study-specific screening procedures. * A histologically or cytologically confirmed advanced solid tumor * ≥ 18 years of age * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors * Karnofsky performance status ≥ 70% * Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after participation. * Females of childbearing potential must have a negative serum pregnancy test. * Laboratory results must meet study criteria. Exclusion Criteria: * Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first infusion * Surgery within 4 weeks prior to first infusion * Known untreated brain metastases * Pregnant or breastfeeding * Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements * Other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
References
Publications (0)
Data not yet available
No reference posted for this study.